psme4a Antibody

What is PSME4 and what is its biological significance?

PSME4 (Proteasome Activator Complex Subunit 4), also known as PA200, is a proteasome regulator that plays crucial roles in protein degradation pathways. It functions as a regulatory cap that binds to the proteasome core particle and affects gate opening and substrate selection. PSME4 has been found to have specialized roles including:

• Involvement in DNA damage response in somatic cells by promoting degradation of histones following DNA double-strand breaks

• Association with the proteasome to promote ATP- and ubiquitin-independent degradation of core histones during spermatogenesis

• Modulation of proteasome activity with significant effects on immunoproteasome function

The protein is primarily localized in the nucleus and cytoplasm, with concentration in the cytosol . With a calculated molecular weight of 211 kDa, PSME4 is a relatively large protein, though it is often observed at approximately 140 kDa in Western blots .

How do constitutive proteasomes and immunoproteasomes differ, and how does PSME4 interact with them?

The constitutive proteasome and immunoproteasome exhibit different proteolytic activities:

PSME4 has been found to bind both constitutive proteasome and immunoproteasome, but with opposing effects. Research has shown that:

• PSME4 increases caspase-like (β1) activity in constitutive proteasomes

• PSME4 decreases tryptic-like (β2) activity

• PSME4 inhibits all immunoproteasome-associated activities (β1i, β2i, and β5i) under inflammatory stimulation

This makes PSME4 the first identified proteasomal subunit that inhibits immunoproteasome activity, with significant implications for immune response and cancer immunotherapy.

What are the critical considerations when selecting a PSME4 antibody for specific research applications?

When selecting a PSME4 antibody, researchers should consider:

Antibody Type and Host:

• Polyclonal antibodies offer broader epitope recognition but potential batch variation

• Monoclonal antibodies provide consistency but limited epitope recognition

• Common hosts include rabbit for polyclonals and mouse for monoclonals

Application-Specific Validation:
The following table summarizes recommended dilutions for different applications based on commercial antibody data:

Epitope Consideration:
Some antibodies target specific regions of PSME4. For example, one commercial antibody is generated against a synthetic peptide between amino acids 503-535 of human PSME4 , while others target regions such as amino acids 1634-1843 or 105-198 .

Species Reactivity:
Confirm cross-reactivity with your species of interest. Many PSME4 antibodies react with human, mouse, and rat samples .

What are the optimal protocols for validating PSME4 antibody specificity?

To ensure antibody specificity, researchers should employ multiple validation strategies:

Genetic Approach:

• Utilize PSME4 knockout or knockdown models as negative controls

• Overexpression systems as positive controls

• Several studies have successfully used PSME4 knockdown cell lines (KP1.9 PSME4_KD) to validate antibody specificity

Multiple Antibody Approach:

• Use antibodies targeting different epitopes of PSME4

• Compare results across different antibody clones

• Verify consistent patterns across different applications (WB, IHC, IF)

Peptide Competition:

• Pre-incubate antibody with the immunogen peptide

• Specific binding should be blocked by the peptide

• Include appropriate controls with irrelevant peptides

Western Blot Validation:

• Verify single band at expected molecular weight (140-211 kDa)

• Include positive control tissues/cells known to express PSME4

• Include negative controls (knockdown/knockout)

Cross-Platform Validation:

• Confirm findings using orthogonal methods (e.g., mass spectrometry)

• Correlate protein detection with mRNA expression data

• Verify subcellular localization across different detection methods

Research has shown that PSME4 antibody validation is particularly important as its expression varies across tissues and cancer types, and its role in modulating proteasome function can significantly impact experimental outcomes .

How can PSME4 antibodies be used to investigate its role in cancer immune evasion?

PSME4 has been implicated in cancer immune evasion, particularly in non-small-cell lung carcinoma (NSCLC). Researchers can use PSME4 antibodies to investigate this through:

Immunoproteasome Activity Assessment:

• Use PSME4 antibodies to immunoprecipitate proteasome complexes

• Compare proteasome activity in PSME4-high versus PSME4-low tumors

• Analyze peptide cleavage patterns using mass spectrometry (MAPP - Mass spectrometry analysis of proteolytic peptides)

Antigen Presentation Analysis:

• Combine PSME4 antibody staining with HLA surface expression analysis

• Research has shown PSME4 depletion significantly increases surface HLA molecules by approximately 30%

• Compare immunopeptidome diversity between PSME4-high and PSME4-low conditions

Tumor Microenvironment Characterization:

• Use multiplex immunohistochemistry with PSME4 antibodies and immune cell markers

• Research has revealed that PSME4-high tumors show decreased CD8+ T cell/Treg ratios

• Analyze cytokine profiles in relation to PSME4 expression

Clinical Correlation Studies:

• Stratify patient samples by PSME4 expression using antibody-based detection

• Correlate with response to immunotherapy

• Research has found that tumors with high expression of PSME4 are less likely to respond to immune checkpoint inhibitors

Key research findings show that the ratio of PSME4 to PSMB10 (an immunoproteasome subunit) yields a significant association with response to immune checkpoint inhibitors across multiple cancer types .

What experimental approaches can resolve conflicting data regarding PSME4 function in different cellular contexts?

When faced with conflicting data about PSME4 function, researchers should consider:

Context-Specific Analysis:

• Use PSME4 antibodies to analyze expression across different cell types and tissues

• Research has shown PSME4 levels vary greatly among different types of cancer

• Examine PSME4 interactome in different contexts using co-immunoprecipitation

Functional Validation through Manipulation:

• Create isogenic cell lines with PSME4 overexpression or knockdown

• Multiple studies have successfully used KP1.9 PSME4_OE and KP1.9 PSME4_KD cell lines

• Assess phenotypic changes in different cellular backgrounds

Mechanistic Dissection:

• Use domain-specific antibodies to understand which regions of PSME4 are crucial for specific functions

• Analyze post-translational modifications that might explain context-dependent activities

• Combine with proteasome inhibitors to distinguish direct vs. indirect effects

Single-Cell Resolution Studies:

• Apply PSME4 antibodies in single-cell analysis techniques

• Research has used single-cell RNA sequencing of CD45+ cells to examine PSME4's effect on immune cell populations

• Correlate with functional readouts at single-cell level

Research has shown that PSME4 can have seemingly contradictory roles: increasing caspase-like activity in constitutive proteasomes while inhibiting immunoproteasome activity . This highlights the importance of context-specific analysis.

How can PSME4 antibodies help identify potential biomarkers for immunotherapy response?

PSME4 antibodies can be instrumental in developing biomarkers for immunotherapy response:

Expression Profiling:

• Stratify patient tumor samples using PSME4 immunohistochemistry

• Research has shown that PSME4 expression is associated with poor prognosis in NSCLC patients (Mantel-Cox p-value = 0.038)

• Combine with other proteasome component markers (especially PSMB10)

Ratio Development:

• Calculate PSME4/PSMB10 ratio as a potential biomarker

• Research across multiple cancer cohorts revealed this ratio is more significantly associated with immunotherapy response than either marker alone

Multiplex Biomarker Panels:

• Integrate PSME4 antibody staining in multiplex IHC panels

• Combine with established markers like tumor mutational burden (TMB)

• Research shows PSME4 contributes significantly to predictive models even when other biomarkers are included (P = 0.0194)

Ex Vivo Response Prediction:

• Use PSME4 antibodies in ex vivo organoid culture models (EVOC)

• Research found tumors with responder hallmarks had significantly lower PSME4/PSMB10 ratios compared to non-responders

• Correlate with IFNγ levels following treatment with checkpoint inhibitors

Research across a cohort of 6 different patient groups with three different cancer types (melanoma, renal, and bladder cancers) treated with immune checkpoint inhibitors demonstrated that PSME4 varies greatly among individual tumors and cancer types, with high expression associated with poorer response to therapy .

How should researchers address inconsistent PSME4 detection across different antibodies and applications?

When facing inconsistent PSME4 detection, consider:

Epitope Accessibility Issues:

• Some antibodies recognize linear epitopes (e.g., 3F11 and 1A11 mAbs bind linear epitopes spanning residues 226-243 and 271-288 of human PSMA)

• Others recognize conformational epitopes (e.g., 5D3 and 5B1 mAbs recognize surface-exposed conformational epitopes)

• Use multiple antibodies targeting different regions of PSME4

• Adjust antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

Sample Preparation Variables:

• For Western blot: Try different lysis buffers and reducing conditions

• For IHC: Compare different fixation methods and antigen retrieval protocols

• For IP: Consider crosslinking strategies (e.g., DSP crosslinking as used in proteasome purification)

Antibody Validation Strategy:

• Implement a step-wise validation approach:

  • Start with Western blot to confirm specific band at expected MW

  • Include positive and negative controls

  • Validate in multiple cell lines/tissues

  • Cross-validate with orthogonal methods

Technical Optimization:

• Adjust antibody concentration based on the dilution table:

• Optimize incubation times and temperatures

• Consider signal amplification methods for low-abundance detection

Research indicates that PSME4 may undergo post-translational modifications or exist in different complexes, potentially affecting antibody recognition .

What approaches should be used to analyze PSME4 expression in heterogeneous tumor samples?

For analyzing PSME4 expression in heterogeneous tumor samples:

Spatial Resolution Techniques:

• Use multiplexed immunofluorescence to co-stain PSME4 with cell type-specific markers

• Implement digital spatial profiling to quantify PSME4 across different tumor regions

• Research shows PSME4 and PSMB10 can be expressed in epithelial tissue, with PSMB10 more highly expressed in lymphocyte infiltrates

Single-Cell Analysis:

• Apply PSME4 antibodies in single-cell protein analysis platforms

• Correlate with single-cell RNA sequencing data

• Research has demonstrated the utility of single-cell analysis to understand PSME4's effect on immune cell populations in the tumor microenvironment

Tissue Microdissection:

• Use laser capture microdissection to isolate specific tumor regions

• Apply PSME4 antibodies to these isolated populations

• Compare with adjacent normal tissue (as done in NSCLC studies)

Computational Deconvolution:

• Implement computational methods to deconvolute PSME4 signal from bulk tissue

• Correlate with histopathological features

• Integrate with multi-omics data

Research on NSCLC has shown that PSME4 expression in tumors needs to be considered in the context of the entire tumor microenvironment, as it affects immune cell infiltration and function . Studies indicate that PSME4 promotes an immunosuppressive environment around tumors and abrogates anti-tumor immunity .

How can researchers distinguish between PSME4 isoforms or post-translationally modified variants using antibodies?

To distinguish PSME4 variants:

Isoform-Specific Antibody Selection:

• Use antibodies targeting regions that differ between isoforms

• Validate with recombinant isoform proteins

• Combine with RT-PCR to confirm isoform expression at mRNA level

Post-Translational Modification (PTM) Detection:

• Use antibodies specific for phosphorylated, ubiquitinated, or otherwise modified PSME4

• Implement enrichment strategies (e.g., phospho-protein enrichment)

• Combine with mass spectrometry for PTM mapping

Size Discrimination Techniques:

• Use high-resolution electrophoresis to separate isoforms

• Apply antibodies that can detect size differences

• Note that PSME4's calculated MW is 211 kDa but is often observed at 140 kDa in Western blots

Functional Validation:

• Correlate isoform/PTM detection with functional assays

• Assess proteasome activity changes associated with specific variants

• Research shows PSME4 can differentially affect constitutive and immunoproteasome activities

Combined Approaches:

• Implement 2D gel electrophoresis followed by Western blotting

• Use immunoprecipitation followed by mass spectrometry

• Apply proximity ligation assays to detect specific interactions

Research has shown that the proteasome regulator PSME4 can exist in different functional states and complexes, affecting its detection and biological activity . Understanding these variants is critical for interpreting experimental results.

How might new antibody technologies advance our understanding of PSME4's role in cancer immunotherapy resistance?

Emerging antibody technologies may provide new insights into PSME4's role in immunotherapy resistance:

Single-Domain Antibodies (Nanobodies):

• Development of nanobodies against PSME4 for super-resolution microscopy

• Real-time tracking of PSME4 dynamics during immune responses

• Potential for intracellular targeting to modulate PSME4 function

Bispecific Antibodies:

• Creation of bispecific antibodies targeting PSME4 and immunoproteasome subunits

• Investigation of proteasome complex formation dynamics

• Potential therapeutic approach to restore immunoproteasome function

Antibody-Based Proteomics:

• Development of comprehensive PSME4 interactome maps using antibody-based proximity labeling

• Identification of context-specific partners in different cancer types

• Integration with functional genomics to identify synthetic lethal interactions

In vivo Imaging:

• Development of PSME4-targeted antibodies for in vivo imaging

• Monitoring PSME4 expression during immunotherapy

• Research has shown that antibodies like 5D3 and its Fab fragment are suitable for in vivo imaging in xenograft models

Research suggests that targeting PSME4 expression or its binding to proteasomes represents a novel therapeutic approach for treating NSCLC and potentially sensitizing tumors to immune checkpoint inhibitors .

What methodological advances are needed to better investigate PSME4's differential effects on constitutive and immunoproteasomes?

To better understand PSME4's differential effects on proteasome subtypes:

Advanced Biochemical Approaches:

• Development of methods to isolate pure populations of PSME4-capped constitutive vs. immunoproteasomes

• Creation of fluorescent reporters for real-time monitoring of different proteasome activities

• Research has established that PSME4 has opposite effects on constitutive vs. immunoproteasomes

Structural Biology Integration:

• Application of cryo-EM to determine structures of PSME4-capped proteasome complexes

• Elucidation of binding interfaces that explain differential regulation

• Development of structure-guided antibodies targeting specific interfaces

Quantitative Proteomics:

• Refinement of MAPP (Mass spectrometry analysis of proteolytic peptides) for higher throughput

• Comprehensive mapping of cleavage patterns in different cellular contexts

• Research has already identified altered cleavage patterns in cancerous vs. normal tissue

Site-Specific Antibodies:

• Development of antibodies recognizing specific proteasome-PSME4 interactions

• Creation of conformation-specific antibodies that distinguish different binding modes

• Application in proximity ligation assays to map proteasome heterogeneity in tissues

Research has shown that PSME4 differentially affects β1 (increases activity) and β1i (decreases activity) subunits , suggesting distinct binding modes or allosteric effects that require further investigation.

How can PSME4 antibodies contribute to developing new therapeutic strategies for cancer immunotherapy?

PSME4 antibodies could enable novel therapeutic strategies:

Target Validation:

• Use of antibodies to validate PSME4 as a therapeutic target

• Research has shown that PSME4 expression correlates with poor prognosis in NSCLC

• Stratification of patient populations based on PSME4/PSMB10 ratio

Therapeutic Antibody Development:

• Creation of antibodies that block PSME4-proteasome interactions

• Development of antibody-drug conjugates targeting PSME4-expressing cells

• Exploration of intrabodies to modulate PSME4 function

Combination Therapy Optimization:

• Use of PSME4 antibodies as diagnostic tools to guide combination immunotherapy

• Research suggests PSME4 status could predict response to immune checkpoint inhibitors

• Development of PSME4 inhibition strategies to enhance immunotherapy efficacy

Ex Vivo Screening Systems:

• Implementation of Ex Vivo Organoid Culture models (EVOC) with PSME4 antibody screening

• Prediction of patient-specific responses to therapy

• Research has demonstrated that PSME4/PSMB10 ratio in EVOCs correlates with immunotherapy response

Research across multiple cancer types has shown that PSME4 modulation could potentially overcome resistance to immunotherapy, representing a novel approach to enhance treatment efficacy .